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The syndrome of congestive heart failure is characterized by 
generalized and organ-specilk increases in efferent sympa- 
thetic activity, with the greatest increase in sympathetic out&w 
being directed to the heart (1). Increased sympathetic out&w 
to the heart may have several adverse effects in&xiii down- 
regclation and desensitization of cxdiac beta-adrenergic re- 
ceptors (2), impaired function and viability of cardiac myocytes 
(3) wd a predisposition to ventricular arrhythmias (4). Recent 
evidence (5) demonstrates that increased cardiac adrenergic 
drive is stron& predictive of mortality, at least in patients with 
heart failure undergoing evaluation for heart transplantation. 
Despite the adverse consequences of sympathetic activation 
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directed to the heart, the modulation of cardiac sympathetic 
outflow by medical therapy in the setting of heart failure 
remains largely unexplored. An agent that may favorably 
reduce central sympathetic outflow to the heart is digoxin. 
Cardiac glyadeq by increasing arterial baroreceptor and 
cardiac receptor nerve d&barge (6-ll), cause an &ease in 
efferent parasympathetic activity and a k&ction in central 
sympathetic outlbv (12). In animal models glycosides reduce 
cardiac effewnt sympathc’k activity (13,14) and increas car- 
dii catecholamitse stores (15). In patients with heart failure 
digoxin reduces plasm norepkphrine concentration (16- 
19), an approximation of gene&ized sympathetic tiivity. 
&diacg@&deshavealsokenshown(M)toreducesympa- 
theticmxvetra&toskektalmusde,adkectmeasweof 
TyTtp&etic~tothe~.The’eilectofdigrednm 
!$ympdeticoutfknvloth!ehearlinhtmlanswithcoagestiwheart 
faihmremaiE3lmlmom. 
Predii which patients will have increased cardiac gym- 
pathetic o&low is dilkdt bemuse the afferent signals leading 
totbbdisaubanceate~~~defined(21).Lthesen~0f 
heart fake, efferent sympathetic activhy to skeletal musck is 
diredyrdatedto iSJUtWSiSlpulmonaryarterypressUrettSSd 
left vennicular lwlg pessures (2523). sid@. sympatbetk 
oll&vwtothehearias~bycafdiacnorepioephriae 
spjilaver,isalso 
p”ssures (2% 
07354@97c96m5M 
m sa735-la97t%)fJtups 
certain, cardiac kympalt.elic activalion in congeslivc ilcart 
failure is associated with elevated central filling prrssu,t .:. 
We hypothesized that digoxin would reduce cardiac sympa- 
thetic activity in patients with heart failure and underlying 
sympathetic activation. To test this hypothesis we studied a 
group of patients with heart failure and elevated filling pres- 
sures, because these patients have been reported (21-23) to 
have increased sympathetic activity. For comparison, we also, 
studied patients with heart failure and normal filling pressures 
and patients with normal ventricular function. To assess the 
effect of digoxin on sympathetic outflow IO the heart. we 
utilized the steady state radiotracer technique (24) to measure 
:he cardiac norcpinephrine spillover response to a single 
imr:!venous dose of digoxin. 
Methods 
Patients. Twenty-four patients with heart failure (22 men, 
2 women; mean age 2: SEM 58 f 2 ycan) with a left 
ventricular ejection fruction ~35% (radionuclide angiography 
[n = lb], cchocardiography [n = I]) participated in this study. 
Four patients were in New York &art Association functional 
class II and 21) were in class 111 c: IV. Twelve patients with 
elcvatcd left ventricular end-diastolic pressure (>14 mm Hg) 
were designated as Grrncp A. The etiolog of heart failure 1~1 this 
group was ischrnric in nine and idiopathic in three patients. 
TrGIImenl included diuretic drugs (II = Id), angiotenscl- 
converting enqme inhibitors (n 7 IO), digoxin (n = 9) and 
amiodarorre (n := 2). Five palicnts with normal filling pressuro 
(left ventricular end-diastolic pressure 514 mm Hg, Group R) 
also received digoxin. The etiology of heart failure in this 
group was ischl:mic in thlce and itliclpathir in two patients. 
‘frcatmcrtf included diuretic drugs (n L ?). angiotcnsin- 
convelting enzyme inbihitors (n 2 2) ilnd digoxin (I: = 2). 
Scvcn patients with hem!Klynamic dat:B similar to those of 
Group B (Gnru co~rr~!gro~p) underwent an identical protocol 
without the administration of digoxin. The etiology of heart 
failure in this group was ischemic in three and idiopathic in 
four patients. Treatment included diuretic drugs (n .= 7). 
angiotensinconvcrting cnaymc inhihiton (n 2 h), digoxin (II .- 
7) and amitdurcmc (n 2). Paticnls participating in thr 
dig&n protocol who were rccciving maintenance digox& 
thcrapj had this medic&ion withheld for a minimrlm of 7 days 
before the sludy date. 
The nor& r’c~nr~~~~br~~nc~/ic. 1 grvrrp included five men and 
ow woman (mu. I LI~C 50 ! 5 yciln). Three paticms had 
ct)t~on;l~ artcry JIwa’iL’. bul M)IIC hild a hishfry of myncardial 
mfarstion. Medicid thrrapy included hta-adrcncrgic blocking 
agents (II = 2). calcium channel hlockmg agents (n = 2). and 
an angiotensinccmvertting enzyme inhihitor (n .= !), 
IX protocol was approved by rhe phical Review Com- 
mitted for Human Ewiin;intation of Ihc :‘nivcrsicj of TG 
romo. Writiea informed conwnt y/a\, trhtaincd in ,111 cuses“~. 
Shady pr&cai. Diagntatic right and fcft hc:lri *.atheterila- 
tion, without udation. was performed fnr.1 the femoral ap 
proaeh. A 7F ?lumnlil~~~~m caarlctcr (rvp‘ (‘G-?tJ-Wf3. 
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Wchstcr Ishoratories) was then placed in the coronary sinus 
from an antecubital vein for dew measurements and sampling. 
A 7F micromanometer-tipped catheter (Milbu Industries) was 
placed in the left ventricle for assessment of contractility (peak 
positive first derivative of left ventricular pressure (dP/dt) and 
filling pressures. The patient was then left undisturbed for a 
minimum of 20 min and until an intravenous infusion of 
tritium-labeled norepinephrine reached steady state concen- 
tration in plasma. Al that point, hemodynamic variables and 
total body and cardiac norepinephrine spillover rates were 
assessed. Digoxin (0.25 mg in IO ml 01 5% dextrose in water), 
was then administered intravenously over 6 min with use of a 
Harvard pump. Hemodynamic and norepill. ihrine spillover 
mcasuremcnts were repeated 30 mm later. In the time control 
group, the same hemodynamic and spillover i;*sasurements 
were performed at baseline and repeated at 30 min. 
Patients were classified by left ventricular enddiastolic 
pressure measurements into either Group A (>I4 mm Hg) or 
Group B (-14 mm Hg) on the basis of hemodynamic data 
recorded before administration of digoxin. This catego:ization 
was performed before the biochemical analysis. 
Norepinephrine spillover merwwemeots. Sympathetic ac- 
tivity was estimated according to the radiotracer technique of 
Esier et al. (24). This method provides the rate at which 
norepincphrine appears in plasma and is therefore an indirect 
measure of effcrcnt sympathetic nervous activity. To assess 
norepincphrine spillover, a . ..~~dy state plasma concentration 
of :I tracer dose of tritium-labeled norepincphrine is required. 
Total hrldy norepincphrine spillovcr is cala:latcd as follows 
(L24): 
Tot:11 h)dy NE ‘:pillwer (pmol/min) 
[‘IlINE infusion rate (dpm/min) 
= Plasma NE &cific activity (dpmipmol) ’ 
where NE = norcpinephrine, [JH]NE = tritiilm-labeled nor. 
epincphrine, and dpm = disintegrations per minute of tritium- 
labclrd norcpincphrine. 
C’ardiac norcpincphrinl: spilltwcr is calculated according IO 
the Fick principle, with a correction for the extraction of 
tritium-labeled norepinephrine across the heart (1,24,25): 
whcrc Nt.,.,, - tramcardiac fractional extraction of tritium- 
lab&d norrpinephrinc. (JH]NE,,,, and t’HINE,, = arterial 
and coronary sinus tritium-labeled norepinephrine conccnrra- 
lions. respectively. NE, and NE,, = coronary sinus and 
-rtcr~al norcpincphrinc concentr&ons. respcctivcly, ,UI~ 
I’SPI: = coronary sinus p&ma How calcufatcd from the 
hr‘nrattrrit and coronary sinus blood Row. 
A nwc dctaikd cbaluation t$ cardiac mwspinephriw 
kineticswus pwf&xrnwd in Md:hc I2 patients in Gruup A sld 
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in all 7 in the time control group. In these patients, the cardiac 
spillover of the intraneuronal norepinephrine metabnlitc, di- 
hydroxyphenylglycol (DHPG), was calculated as the product of 
its venoarteriaf gradient and coronary sinus blood flow (25.26). 
Cardiac spillover of tritium-labeled DHPG was also calculated 
by the same method (25.26). Tritium-labeled DHPG spillover, 
which can only occur aa a result of neuronal uptake of 
tritium-labeled nore,inephrim, provides an index of neuronal 
re-uptake of norepi’ ephrine (25,26). 
Radiotmcer pw~watioo and ioliis!sn. Trifium-iabekd 
norepinephrine (L-I?J,~‘H]NE, New England Nuclear) was 
diluted in sterile 0.2~moffliter acetic acid in saline solution with 
IO-mmoi/liter ascorbate, sterilized by filtration through a 
0.22~pm Millex-GV filter and packaged in 4-ml aliquots that 
were stored at -70°C until use. The radiotracer was adminis- 
tered intravenously as a IQ@Ji priming bolus followed by a 
continuous infusion of 1 Lo 1.2 PCiimin. Control mcdsure- 
ments were performed ~60 min after initiation of the radio- 
tracer infusion to ensure steady state concentration in plasma 
(27). 
Analysis of plasma cateehulamines. Samples were trans- 
ferred immediately to ice-chilled tubes containing an antico- 
agulant (ethylenediaminetetraacetic acid). The plasma was 
separated by centrifugation at 4°C and then stored at -70°C 
until assayed. After the addition of dihydroxybenzlamine 
(DHBA) as an internal standard, the catechols were extracted 
by adsorption on alumina. After elution from the alumina by 
the addition of O.Zmol/liter perchloric acid, the cacechols were 
separated by isocratic ion pair chromatography on a reversed 
phase column. The high performance liquid chromatography 
system consisted of a multisolvent delivery system model 6OOE 
pump, a model 7171 automatic sample injector (Waters Asso- 
ciates) and a Zorbax %-Cl8 4.6 X 1%mm column (Chro- 
matographic Specialties Inc., Brockville, Ontario. Canada). 
Detection of the compounds was performed by a model 
Coulochem II <zoulometric detector consisting of four coulo- 
metric cells in series @A). Data analysis (electrode 4 set at 
-0.38 V) was performed by Millennium 2010 chromatography 
manager (Waters Associates). Fractions containing tritium- 
labeled norepinephrine and DHPG in the efffuent, collected 
distal to the electrochemical cell, were assayed by liquid 
scintillation spectroscopy. Recovery of catecholamines from 
alumina was --75%. and was corrected to the internal standard 
(DHBA). The detection limit of the method was -0.1 nrnoU 
liter, and peak area was linear from 0.1 to 50 nmol/litcr. 
Intraassay tn T 8) and intcrassay (n = 14) coefficients of 
variation were. respectively. 1.9%’ and 3.0% for the determi- 
nation of endogenous norepinephrine and 8% and 11% for 
endogenous DHPG. 
HclaodyaruekoIIclom~~was~ ts. Leftvcn- 
tricular contractility (peak positive dP/dt) and filling pressures 
wcrc assessed with a micromanometer-tipped catheter placed 
in the kft ventricle. Femoral ancry pressure was monitored 
wilh an 8F :ide arm sheath (Cordis Laboratories). I%e elec. 
trocardn~, femoral artery preswrc, kft ventricular pres- 
sure and its first dcri\ative (amtinuous electronic dillerentia- 
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Table I. Baseline Characteristics of the 30 Patients 
157 
LVEF 
HR 
PAmcm 
Cl 
L dilJP 
F-h 
FA PP 
tdP/dt 
CANFSP 
Patients With Normal 
Ventricular Fmmion 
(n = 6) 
- .-.- -.- 
sv c 5 
6v.!3 
14: 2 
2.7 t. 0.1 
II r2 
153 2 10 
7725 
i377tw 
III3 f 41 
Patients With Heart Failure 
Time ContFol 
Group A GwB Gmup 
(n = 12) (n = 5) (n = 7) 
?I + 1. 31 + 3’ 152 I’ 
tl6.tJ ,(4 : 4 sn? IO 
30 t 3’ II 2 2t 33 + 5’ 
l.x+u.I* 2.7 + 0.3t 1.8 ? 0.2 
25 t 2’ Vtl 24 t 4” 
Es+7 137: 7 1t1+7 
56 t 4’ 76 + 4 5427 
vwtvw l020? 122 706 ‘i 54’ 
263 ? 70 151 t 5s 33v ? 73 
‘p < 0.0s vcmu nwmal gr”“uup. tp . UM YenIl\ alup A. Left ventrictdw 
ettd-dimtalic pwsure (LS’EDP [mm Hgl) was not annpted beween Group A 
pqd Croup 6. Data presented are mean value t SEM. CANESP = cardiac 
norepmephrine spillover @moUrnin); Cl F cardiac index (litem/min per m*): FA 
PP = femural artery pulse pressure (mm Hgj: F& = femoral artmy systobc 
prwure (mm Hg); HR = bean rate (beztsimin); LVEF = left vetttktdat 
ejection fraction (a); P&.. = mean pulmonary attery pressure (mm fig); 
tdP/dt = peak positive lint derivative of left ventricular pressure (mm Hgk). 
tion) were recorded on a strip chart recorder. Measurements 
were obtained by averaging 2 I5 cardiac cycles. 
The coronary sinus thermodilution flow catheter was posi- 
tioned under lluoroswpic guidance and correct placement was 
confirmed with radiographic cOntrast injection. The external 
thermistor was advanced 22 cm past the ostium of the 
coronary sinus to avoid reflux of right atriil blood (28). A 
amstant position was maintained during the study by compar- 
ison with anatomic landmarks. Room temperature 5% dex- 
trose in water was infused at 35 ml/min by Harvard pump for 
coronary blood flow measurements, which were performed in 
triplicate according to the method of Ganz et al. (29). 
Statlstkal l natysi~. All data are presented as mean 
value -t SEM. Statistical analysis was performed in SAS (SAS 
release 6.10, SAS Institute Inc.). Between-group comparisons 
of baseline characteristics were ma& by a one-way analysis of 
variance adjusting for multiple comparisons (Bonferroni). 
Within-group and between-group comparisons of changes 
between control measurements and 30 min after digoxin 
administration (and time control) measurements were made 
using a multivariate anatysii of variamc (MANOVA) with 
appropriate contrast statements for all mmparisons. A p value 
of less than O.O!i was required for statistical signitkance. 
Results 
Baselii characteristics (Table I). The 12 patients with 
heart failure in Group A (left ventricular end-diastolic pres- 
sure ; I4 nn Hg) had a mean left ventricular enddiastolic 
pressure of 25 C 2 mm Hg (rzngc I6 to 3x). The tive patiena in, 
Grarpr3(cfiwXtricu!ai&-diast&peswe~I4mmHg)had 
ameankftventrkularer&%astolicpressumof9~ ImmHg 
(range4tol2).InamparisonwitbGroupB.thepatientsin 
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Table 2, Hemodynamic, Plasma (Btecholamine and Norepinephrine Spitlower Responses 
b---e- -- 
Pntirntr With llcarr Fadurc -~ 
Pv~irnlr Wilh Normal Gnq A :inmp B Time Ctihlml Group 
Vcntriculur Fun&n (n b) (n 12) In -. S) (w= 7) -- --- 
Dig - 
------ ---_------ 
c c Dig c. Dig c 30 min 
HR 69 -r 3 69 % 4 x6+5 MS i 5 8454 Xl 24 98 2 10 % 2 IO 
LVEDP II +-2 102 1 2522 25-3 9+1 72 I 24 2 4 23 5 4 
h‘% 153 _c IO 155 + 8 12827 132 5 6 137 + 7 141 2 IO 11827 118~h 
FA PP 77 -r 5 80%6 56 + 4 59 _+ 4 7b “- 4 79i-9 54 c 7 56 f 7 
+dPidl 3.377 +_ 99 1381 2 92 99Glc9u 1027 + 55 1020 + 121 1053 f 131 7Ob t 54 716 c 58 
CSBF I43 f II 14x L 15 176 f !I IbS .Z ?I 17s t I4 Ihl + 14 185 2 35 IYI ?z 34 
NL,, 1.1 :o..l I,/ ? 0.2 2.2 5 0.4 I.0 i 0.3 I .4 ! 0.4 I .4 t (I.4 3.2 ? 0.X 3.0 c 0.x 
W I.4 t 0.4 1.4 t Il.3 3b? 1.1 3.2 r 1.w 2.0 c (I.7 2.5 f 0.W 4.5 ? o.ii t.b ?: 0.8 
TBNESP 3.23 t Oh9 3.34 t 0.5v 4.02 ‘f 0.68 4 44 f Rb5 4Ih? 1.m 4.62 * I.32 b.25 ? 0.57 6.44 z 0.67 
NE,., (I.71 i: (1.07 0.7l1 t o.oh 031 1 0.03 0.61 ? rl.tnt o.sv * 0.05 03x 3 0.07 0.54 f: 0.07 0.50 + 0.07 
CANECL 71 t I4 7H t II ho t x 61 + 4 bV f 7 61 *_ 7 56 i- 5 5b+ 5 
CANESP 103 .r 41 vu c 37 2h3 ? 70 2IX + h3 I51 + 55 IV1 t 6X' 339 c 73 339 2 65 
-- ..-- 
*p < OJI5 and tp < (I,01 wrsus clmtwl value for xithiwgroup compwium,. Data presented we mean value + SEM. C = conlml; CANECL = cardiac 
norepincphrinc clearance (ml/mm): CSBF = coronary 6iw.s hltd Row (mllmin); IJig = digoxin; NE,, and Nf&,. = arterial and coronary rinus norepinephrine 
waeeatration (nmcl4iter. respeclivrly): NE,,, = tramcardiac vu dm-labeled norcpinephrine cxtrdclion ($6): TBNESP = lotal body norepinephrinc qpillover 
(nmol/min): other ahhrtvtatmn~ 4s m Talk 1. 
Group A had significantly lower values for cardiac index and 
higher mean pulmonary artery pressures. Although the mean 
value for cardiac norepinephrine spillover was higher in Group A 
than in Group B, the difference was not significant. Baseline 
hemodynamic and nemochemical values in the time control 
group with heart failure were similar to those in Group A. 
Baseline characteristics for all groups are summarized in Table 1. 
Humudynamic rcspunses (Tabie 2). There were no changes 
in any hemodynamic variable after administration of digoxin in 
Group A, Group Band the normal ventricular function group. 
There were also no hcmodynamic changes over 30 min in the 
titnc control group. 
Crrdinc and tutal body norepinephrlne spillover responses 
(Table 2. Fig. I and 2). In G”tuup A, there were no significant 
changes in arterial uorepinephrine concentration, total body 
norepinephrine spillover or total body norepinephrine clear- 
ance after administration of digoxin. However, coronary sinus 
norepinephrine concentration decreased from 3.6 t 1.1 to 
3.2 4 1.0 nmol/iiter after digoxin (p < 0.01). Similarly. cardiac 
norepinephrine spillover dccreascd from 263 i’ 70 to 21X L 
62 pmol/min after digoxin (p e.: Wttl). The indivtduat cardiac 
norcpincphrine spillover rcsponuzs to digoxin are illustrated in 
Figure I. There was a small but significant increase in the 
transcardiac fractional extraction of tritium-labeled norepi- 
nephrioc: however, there was no change in cardiac norepi- 
nephrine clcatancc (Table 2). 
In Gnnqr 8, there wcrc also no changes in arterial norcpi- 
nqrhrinc concertiration. total body norcpincphrine spillovcr or 
total body norepinephri~tr clearance after administration of 
digoxin. In contrast to tmdings in Group A. coronary sinus 
ncr-pinsphrine concctttration increased (fmm 20 i: ft.7 to 
2.s f 0.7 nmnllita) after digoxin (p < 0.01) as did cardiac 
ntuegmepitrine spillover (from ICI Z 55 to 191 2 68 pmohmin) 
(p < 0.05, Fig. 1). There was a trend to a decrease in cardiac 
norepinephrine clearance (p = 0.1, Table 2). 
In rhe rime conrrolgmup, there were no changes in catechol- 
amine concentrations or spillover rates over a 30-min period 
(Table 2, Fig. 2). In the normal venMdarjiwtion group, there 
were also no catecholamine or norepinephrine spillover 
changes from control to 30 min after digoxin administration 
(Table 2, Fig. I). 
Figure 1. Cardiac norepinephrine (NE) spillover response to digoxin 
in individual patients with group mean values (-) for 17 patients with 
congestivs heart failure (CHF) (Group A and Group 8) and 6 patients 
with normal ventricular function (Normal). Group A comprised 12 
patients with severe failure and left ventricular end-diastolic pressure 
>14 mm Hg, and Group B, 5 patients with less severe failure and left 
ventricular end-diastolic pressure ~14 mm Hg. Spillover values are 
shown for the control measurement (C) and 30 min afler digoxin 
administration (0). “p c 0.0.5 and tp r, (I.01 versus the control value 
for within-group comparisons. 
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Ptgure 2. Cardiac norepinephrine (NE) spillover values in individual 
patients with group mean values t-) for the seven patients in the time 
control group. Spiker values are shows for the mntrol measurement 
(C) :tind at 30 min. 
Behveen-group comparisons of cardiac norepioephrhe 
spfllover respnnses. The decrease in c;rtdiac norepinephrine 
spillover after dignxin administration in Group A was signifi- 
cantly different ttiim th. responses in the normal ventricular 
function group (p < 0.05) Group B (p < 0.01) and the time 
control group (p < 0.05). 
Group A and Group B differed in several hemodynamic 
variables (Table 1). A retrospectivefy defined analysis demon- 
strates that there appears to be- a continuous relation between 
the cardiac spillover response to digoxin and certain baseline 
variables. For example, linear regression analysis of all the 
patients with heart failure reveals a significant relation be- 
tsveen left ventricular ejection fraction and the change in 
cardiac norepinephrine spillover seen with dignxin (5.2x - l$8, 
r = 0.62, p = 0.01; Fig. 3). Similarly. there was a relation 
between cardiac index and the cardiac norepinephrine spill- 
over response to digoxin, although in this case it was of 
borderline statistical significance (36x - 96, r = 0.41, p = 0.1). 
Dlhydroxypbenylglycal cardfac spillover. The cardiac spill- 
over of tritiumdabeled DHPG tended to increase both in 
Group A (6,375 t 1,466 vs. 7,604 2 I.358 dpm/min, [control 
vs. digoxin, p = 0.211) and in the time control group (5,896 z 
2,217 vs. $352 2 3,088 dput/min [control vs. 30 mitt, p = C.lg]). 
There were no changes in the cardiac spillover of endogenous 
DHPG in either group (data not shown). 
Digoxin levels. The serum digoxin level at 30 ruin was 4.g + 
0.5 nmolihter in Group A, 4.3 5 0.7 nmohliter in Group Band 
4.4 + 0.3 nmohliter in the normal ventricular function group. 
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Ftgurs 3. Scattergram of change in cardiac norepktephrine (NE) 
spillover with iligoxiu versus left ventricular ejection fraction by 
radionuclide ventricutography, in patients with heart failure who 
received digoxin (Group A and Group B). 
Patients in Group A (elevated tilling pressures) had a tower 
cardiac index and higher pulmonary artery pressures than did 
patients in Group B (normaf filling pressures). Dioxin caused 
a cardiac sympathoiibitory effect only in Group A. We 
emphasize that this result was probably not based on dither- 
ences in filling pressures alone. It appears liiely that the 
observed effect of digoxin in the patients in Group A resulted 
from the severity of their heart failure syndrome. Ilk concept 
is supported by the significant relation found between the 
sympathoinhibitory effect of digoxin and left ventricular ejec- 
tion fraction. Because a decrease in sympathetic tone may have 
long-term beneficial effects in heart failure, our results may 
provide an explanation for earlier studies that demonstrated a 
favorable hemodynamic responx to digoxin during sustained 
therapy only in patients with alnormal hemodynamic status at 
baseline (30). 
keviuus invtstigatlons. The effect of cardiac gfycosides on 
peripheral sympathetic activity in patients with heart failure 
has been previously described. Although digoxin has been 
shown (16-19) to reduce plasma norepinephrine concentra- 
tion, a general index of sympathetic tone, Goldsmith et al. (31) 
found no effect of a smafl noninotropic dose of cedilanid-D on 
total body norepinephrine spillover. We also found no change 
in total body norepinephrine spillover, suggesting that this 
meacure may be relatively insensitive to small changes in 
sympathetic outflow occurring in specific vascufar beds. Gn the 
other hand, Ferguson et al. (20) showed that de&no&k 
directfy decreased measured skeletal muscle sympathetic nerve 
act$ty. We considered it important to extend this observation 
to the heart because the symputhetiq nemous system is highly 
differentiated and effects observed in the periphery may not be 
representative of adrenergic drive to the heart. Consistent with 
the observation of Ferguson et al, in the periphery (20). we 
demonstrated that digoxin reduced sympathetic outflow to the 
heart in patients with severe congesthe heart failure. 
lWn!hl lcebrnisor l&s inktigation fciatsefi on ekr- 
ent sympathetic outflow to the heart. lk possible afferent 
Discussion 
The novel finding of the present investigation is that digoxin 
caused a red&on in cardiac norepinephrine spillover in 
patients with heart failure and decompensat ed hemodynamic 
status, as defined by elevated ventricular filling premres. 
Selecting patients based on elevated kft ventricular end- 
di+stolic presume resulted in a group with severe heart failure. 
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mechanisms responsible for the observed dccrcasc in cardiac 
norepinephrinc spillover were not directly evaluated. Both the 
cent*ut and nerve terminal effects of glycosides cause increased 
noxcpinephrine rclcasc (32.33) and, therefore, do not explain 
our lindings. We speculate that the decrease in cardiac nor- 
epincphrine spillover was related to improved baroreceptor 
sensitivity. It is unlikely that it resulted from increased barore- 
ceptrr stimulation, because there were no detectable inotropic 
or hemodynamic changes in response to digoxin. This finding 
suggests, but does not prove, that digoxin sensitized barore- 
captor function. The reduction in cardiac norepinephrine 
spillover may have been limited to Group A because of a 
greater underlying impairment in ha.oreceptor control of 
sympathetic outflow m patients wit;) more advanced heart 
faihrre (34). 
Cardiac norepinephrine ,pillovcr increased in the heart 
failure group with normal hemodynamic smtus (Grout B). 
This unexpected result suggests that digoxin has the potential 
to increase cardiac sympathetic activity m patients with com- 
pensated heart failure. The present findings are only suggestive 
because the observation involves a small number of patieots 
nnd no control group with similar hemodynamic status was 
included. Furthermore, the mechanism of such an increase in 
cardiac norcpinephrine .spillover in patients with compensated 
heart failure is difficult to explain. Cardiac glycosides increase 
norcpincphrine release through both central sympathoexcit- 
atory effects (32) and direct nerve terminal effects (33). These 
sympathoexcitatory effects have not been demonstrated in 
human studies and wern unlikely to have occurred in the 
present study because of the small dose of digoxin that was 
used. Ncvcrtheless, the possibility that digoxin increases car- 
diac norepinephrinc spillover in patients with compensated 
heart failure raises an important new hypothesis that merits 
further investigation. 
Cardiac norcpincphrinc spillovcr has been demonstrated in 
animal models to hc rcprcscntative of cardiac sympathetic 
nerve firing ralc (2h). Howcvsr. there are scvcral other vari- 
ubles that may effect norepinephrine spillover, such as coro- 
nary blood Row, capi.lary permeability to norepinephrine (35) 
and norcpincphrine reuptake (25). In Group A, the group in 
which norepinephrine spillover was reduced, there was an 
increase in the fractional extraction of tritium-labeled norepi- 
nephrine consictent with increased rcuptake (36). However, 
the tritium-labeled DHPG spillover responxs in this group do 
nc’! ClIPr*tt an intrr:lsc in rcuptakc. Tritium-lahcled DHPG 
itriscs from the intracicuronal mct&olism of trilium-labeled 
norepincphrine that has been captured by neuronal reuptake 
(2S.26). Increased reuptake increases the intraneuronal con- 
centration of tritium-lab&d norcpinephrine. causing an in- 
crease in the cardiac production of tritium-labeled DHKi. The 
tritium-labeled DHPG spillttver responses wcrc similar ir, 
Group A and the time controls group. suggc*ti:& that no 
augmenlation of Ieuptake occurred in Group A. The tir,s. 
dependent increa% chcrved in both groups h;r\ been P! own 
(3) to result from the intraneuronal accumulation of Mum- 
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labeled norcpinephrine with ongoing intravenous administra- 
tion. 
Study limitations. Limitations to the experimental ap 
preach used in the present study must be considered. This was 
not a blinded or randomized study. However, all of the 
hemodynamic data were ana!yzed, and the patient assignments 
(Group A vs. Group B) were made before the biochemical 
analysis. Furthermore, the investigators performing the bio- 
chejlical analysis had no knowledge ‘of patient status. The 
absence of any change in norepinephrine spillover in the time 
control group supports our conclusion that the decrease in 
spillover in Group A resulted from the administration of 
digoxin and was not a function of time. We cannot rule out a 
time effect as the cause of the increase in cardiac norcpineph- 
rine spillover observed in Group B. 
Our protocol did not include an assessment of baroreceptor 
function. However, afferent control of sympathetic outflow was 
considcrcd in the design of this experiment. A low dose of 
digoxin was chosen to minimize hemodynamic responses that 
would haie been likely to reduce sympathetic outflow without 
invoking any primary autonomic effects. In addition, a detailed 
and direct assessment of both left ven:ricular contractility and 
hemodyszmic variables was performed to define the stimulus 
to afferent control of sympathetic outflow, and to rule out any 
change in this stimulus with the infusion of digoxin. 
This study was an acute physiologic assessment of the 
cardiac sympathetic effects of a single dose of intravenous 
digoxin. The observed acute reduction in cardiac sympathetic 
activity does not provide information on whether similar effects 
would be present with long-term oral administration of 
digoxin. The recent report (19) of long-term benetitsof digoxin 
therapy on measures of heart rate variability in patients with 
heart failure suggests that the cardiac autonomic effects of 
digoxin therapy may persist with long-term use. 
Conclusions. A reduction in cardiac sympathetic activity 
was demonstrated after the admmistration of a small intrave- 
nous do= of Jig&n. This effect occurred in the absence cf any 
measurable motropic or hemodynamic changes, suggesting a 
primary autonomic mechanism. The finding of cardiac sympa- 
thoinhibition was limited to patients with severe heart failure, 
disturbed hemodynamir status and sympathetic activation, 
suggesting a potentially beneficial role for digoxin in modulat- 
ing ncurohormonal activation in this group of patients. 
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